TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Arms & interventions
Outcome measures
Primary
Changes in ctDNA from baseline, on-treatment and post-treatment blood samples.
Assess ctDNA kinetics using ctDNA clearance factors such as time to clearance, best overall clearance rate, best confirmed clearance, and time to ctDNA recurrence and correlate with standard of care therapy real-world outcomes such as overall survival, progression-free survival, time to next treatment, and time to treatment discontinuation.
Time frame: 5 years
Secondary
Generation of DNA, RNA, immune and other multiomic datasets.
Time frame: 5 years
Eligibility criteria
Study locations (31)
Alabama Oncology
Birmingham, Alabama, 35233
PIH Health Whittier Hospital & PIH Health Physicians
Whittier, California, 90605
Eastern CT and Hematology and Oncology Associates
Norwich, Connecticut, 06360
Cancer Specialists of North Florida
Jacksonville, Florida, 32256
Morehouse
Atlanta, Georgia, 30310
Piedmont Healthcare
Atlanta, Georgia, 30318
Southern Illinois Healthcare
Carterville, Illinois, 62918
Hope and Healing Cancer Services
Hinsdale, Illinois, 60521
Cancer Care Specialists of Illinois
O'Fallon, Illinois, 62269
Illinois Cancer Care
Peoria, Illinois, 61615
Northwest Oncology and Hematology
Rolling Meadows, Illinois, 60008
Fort Wayne
Fort Wayne, Indiana, 46804
Goshen Center for Cancer Care
Goshen, Indiana, 46526
St. Claire Healthcare
Morehead, Kentucky, 40351
Frederick Health Regional System
Frederick, Maryland, 21702
Southcoast Centers for Cancer Care
Fairhaven, Massachusetts, 02719
Hannibal Regional Healthcare System, Inc.
Hannibal, Missouri, 63401
Lake Regional Health
Osage Beach, Missouri, 65065
Mosaic Life Care
Saint Joseph, Missouri, 64506
Oncology Hematology Associates
Springfield, Missouri, 65807
Hope Cancer Care of Nevada
Las Vegas, Nevada, 89103
Cancer Care Specialists - Reno
Reno, Nevada, 89511
New Jersey Cancer Center
Belleville, New Jersey, 07109
Regional Cancer Care Associates
Belleville, New Jersey, 07109
Hematology Oncology Associates of Central NY
East Syracuse, New York, 13057
Cayuga Medical Center
Ithaca, New York, 14850
Sanford Roger Maris Cancer Center (Fargo)
Fargo, North Dakota, 58102
Aultman Medical Group
Canton, Ohio, 44710
Taylor Cancer Research Center
Maumee, Ohio, 43537
Cancer Care Associates of York
York, Pennsylvania, 17403
Cancer Care Northwest
Spokane, Washington, 99216
References
- Thomas M. Pharma and the benefits of Real World Data. Drug Discovery World (DDW). Published November 4, 2021. Accessed May 5, 2023. https://www.ddw-online.com/trends-analysis-pharma-and-the-benefits-of-real-world-data-13702-202111/
- Office of the Commissioner. Oncology Real World Evidence Program. U.S. Food and Drug Administration. Accessed May 5, 2023. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-real-world-evidence-program
- Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018 Sep;15(9):577-586. doi: 10.1038/s41571-018-0058-3.(PubMed)
- Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, Singh H, Philip R, Pazdur R, Beaver JA. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023 Feb;11(2):e005344. doi: 10.1136/jitc-2022-005344.(PubMed)
- Grayson N. Real-world data can help make better drugs and do it faster. STAT. Published May 2, 2018. Accessed May 5, 2023. https://www.statnews.com/2018/05/02/real-world-data-drug-development/
- Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; Draft guidance for industry. Accessed September 8, 2023. https://www.fda.gov/media/158072/
- Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, Sorrells S, Baker T, Chang A, Michuda J, Iguartua C, MacNeil S, Shah K, Ellis P, Yeatts K, Mahon B, Taxter T, Bontrager M, Khan A, Huether R, Lefkofsky E, White KP. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019 Mar 22;10(24):2384-2396. doi: 10.18632/oncotarget.26797. eCollection 2019 Mar 22.(PubMed)
- Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019 Nov;37(11):1351-1360. doi: 10.1038/s41587-019-0259-z. Epub 2019 Sep 30.(PubMed)
- Finkle JD, Boulos H, Driessen TM, Lo C, Blidner RA, Hafez A, Khan AA, Lozac'hmeur A, McKinnon KE, Perera J, Zhu W, Dowlati A, White KP, Tell R, Beaubier N. Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA. NPJ Precis Oncol. 2021 Jul 2;5(1):63. doi: 10.1038/s41698-021-00202-2.(PubMed)